The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents. The details were published by the European Patent Office (EPO) when the 2020 official data relating to the number of patent applications was released.
This is a significant milestone for Chiesi, which submitted a total of 38 applications to the EPO over the course of 2020. It was also achieved as a result of the Group’s well-defined strategy aimed at consolidating patent cover to protect its numerous Research & Development projects.
As Antonio Campinos, President of the EPO, explains: “Despite the fact that Italy is one of the countries hit hardest by the pandemic, its companies and inventors managed to file a record number of patent applications in 2020” and "This is no easy task, and it is encouraging news because we know that research and science will ensure a more sustainable world and that innovation is the driving force behind economic recovery".
Although 2020 was a difficult and challenging year, it was not able to halt our ability to innovate, and nonetheless generated significant results both for Italy and the Chiesi Group.
“We are proud to have reached this milestone, which above all represents a constant commitment to Research and Development for our Group, with the aim of improving the quality of life of people all over the world – commented Ugo Di Francesco, CEO of the Chiesi Group -. A commitment for which our thanks go to more than 900 Chiesi researchers at the Group’s 7 research centres in Parma (Italy), France, the UK, Sweden, the US, Canada and China”.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.